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Antimicrobial resistance (AMR) is a steadily increasing 
global problem, and drug- resistant pathogens kill at least 
25,000 infected people annually in the European Union 
alone1 (Box 1). The development of AMR is limiting the 
number of antibiotics that can be used to successfully 
treat infections, especially if the empirical prescription 
of antibiotics is necessary. The European Centre for 
Disease Prevention and Control (ECDC) has estimated 
that to date 30–50% of all antimicrobials prescribed to 
human patients are unnecessary2, and over- prescription 
of antimicrobials further promotes the development and 
spread of resistance.
Antimicrobial susceptibility testing (AST) aims to 
ensure that suitable antibiotics are prescribed and to 
monitor the selection and emergence of resistant path-
ogens in infected individuals. Information on local 
patterns of antimicrobial susceptibility can be collected 
using AST, so that policies guiding the empiric choice of 
therapy can be based on current data on local resistance 
trends (also known as the local or institutional antibio-
gram). AST can also help to identify isolates with defined 
resistance mechanisms of major interest to infection pre-
vention and control (for example, extended- spectrum 
β- lactamase producers, carbapenemase- producing 
Enterobacteriaceae, methicillin- resistant Staphylococcus 
aureus (MRSA) and vancomycin- resistant enterococci). 
Furthermore, AST is key for the assessment of resistance 
incidence and prevalence in epidemiological studies that 
examine the origin and spread of resistance, includ-
ing studies on the effectiveness of measures taken to 
counteract spread.
Several different technical means are available for 
identifying the causative agents of microbial infections 
and deciding on a suitable course of treatment at differ-
ent stages of the diagnostic pipeline (Fig. 1). However, 
in terms of actually facilitating targeted antimicrobial 
therapy, it is important to note that some clinical micro-
biology laboratories in different global geographical 
regions may not have access to the currently most pop-
ular and commercially available AST platforms. These 
platforms include several semi- automated systems and 
manual tests such as, for example, the application of 
antibiotic gradient strips and disk diffusion methodol-
ogy. As a technique, AST infers the concentration of an 
antibiotic that is required to inhibit multiplication of a 
microorganism in vitro and that would be achievable 
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in patients. This can be accomplished via growth- based 
(phenotypic) or molecular (genotypic) methods. It 
is noteworthy that genotypic methods mostly detect 
resistance factors, whereas phenotypic methods enable 
real susceptibility testing. Phenotypic AST detects the 
arrest of bacterial cell growth in the presence of static 
or cidal antimicrobial agents3. Genotypic AST attempts 
to identify specific resistance genes or genetic muta-
tions using molecular or genomic (usually DNA- based, 
amplification- based or sequencing- based) methods. 
Genotypic methods are surrogates for AST, and sus-
ceptibility has to be validated with phenotypic tests. 
However, genotypic testing is very useful and fast (for 
example, testing for the presence of the resistance deter-
minants mecA and mecC for the identification of MRSA 
can be performed in minutes). Conversely, phenotypic 
AST may not always accurately reflect the underlying 
genotype of a microorganism, and therefore, additional 
phenotypic testing may be required. Finally, local epide-
miology may greatly affect test performance and utility 
as, for instance, increased prevalence of hard- to-detect 
resistance traits may skew test performance.
In current clinical microbiology laboratories, AST 
is usually performed after a bacterial infectious agent 
has been cultured and identified at the species level. 
However, AST is time consuming, as it involves regrowth 
of the organism in the absence and presence of the rele-
vant antibiotics. Qualified laboratory scientists who are 
proficient in the use of AST may not always be available 
during a particular shift during the day. Often, data are 
not available until the end of a full test run or final val-
idation of the complete data set. It is crucial to improve 
laboratory procedures and staffing hours for the clini-
cal laboratory to ensure effective testing. Furthermore, 
current AST turnaround times are usually between 12 h 
and 48 h. So- called rapid testing, defined as being fea-
sible within an 8-h working shift, supports antibiotic 
stewardship programmes and promotes the prudent 
use of antimicrobials4. Although the AST platforms that 
are currently most used are robust and represent added 
value to the clinical diagnostic microbiology laboratory, 
their main shortcoming is a somewhat long time to 
result (TTR) and a lack of full automation, which may 
hinder the accurate prescription of antibiotics. From a 
basic microbiological perspective, it has to be realized 
that our changing understanding of current antibiotic 
resistance mechanisms, the discovery of new mecha-
nisms, epidemiological aspects, variation of the growth- 
associated lag time, heterogeneity of resistance and the 
occasional need for pre- diagnostic induction of resist-
ance may all provide important barriers when applying 
AST. Therefore, to facilitate targeted (and personalized) 
antimicrobial prescribing practices and to help reduce 
the increasing global burden of antibiotic resistance, 
there is an urgent need for the development and imple-
mentation of novel and truly rapid AST platforms (that 
is, results being available in 30 min to 1 h)5.
Developments in the field of rapid AST platforms 
have been slow over the past decade6,7. This can be owing 
to suboptimal sensitivity and specificity, somewhat high 
purchase and testing costs and the lack of rapid result 
reporting for the care- giving physicians. Moreover, the 
development and implementation of new AST platforms 
may be slowed by other factors, including considerations 
relating to the actual number of antibiotic targets to be 
included in the new platform, post- developmental val-
idation in laboratory and clinical settings, geographical 
and institutional differences in the optimal antibiotic 
target menu, issues regarding legal and intellectual prop-
erty (IP) aspects, cost- effectiveness, acceptance of new 
AST by end users, regulatory approval and the need for 
local expertise. In addition, very major errors (that is, 
false antibiotic susceptibility) and major errors (that 
is, false resistance) are a constant cause of concern. The 
European Committee of Antimicrobial Susceptibility 
Testing (EUCAST) and the Clinical and Laboratory 
Standards Institute (CLSI) are vigilant in regard to iden-
tifying these shortcomings. The European Commission 
aims to standardize all innovations in the field of rapid 
AST, which is also being promoted by the European 
Food Safety Authority (EFSA), the European Medicines 
Agency (EMA) and the ECDC.
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Box 1 | combating antimicrobial resistance*
to tackle the spread of antimicrobial resistance (aMr) in humans, animals and the 
environment, we aim to have implemented national action plans, based on a 
One-Health approach, well underway by the end of 2018. we will promote prudent 
antibiotic use and strive to restrict therapeutic use. responsible use of antibiotics in 
food- producing animals does not target growth promotion. treatments should be 
available through prescription only. we will strengthen public awareness, infection 
prevention and control and improve the understanding of the issue of antimicrobials in 
the environment. we will promote access to affordable and quality antimicrobials, 
vaccines and diagnostics. we highlight the importance of fostering research and 
development, in particular, for priority pathogens as identified by the wHO. we call for 
a new international research and Development Collaboration Hub to maximize the 
impact of existing and new antimicrobial basic and clinical research initiatives as well as 
product development.
*the authors’ version of the statement by the european Commission on the global antimicrobial 
resistance problem, issued during the G20 meeting in Hamburg, Germany (G20 Leaders’ 
Declaration: shaping an interconnected world, published 8th July 2017).
Perhaps the most important factor for consideration 
is the TTR, as many clinical studies have shown that a 
delay in adequate antibiotic treatment for severe infec-
tions increases mortality8. TTR may be particularly 
important when the health- care focus is on the rapid 
diagnosis and treatment of antimicrobial- resistant path-
ogens in settings outside of routine hospital- based care 
and where multidrug- resistant organisms are likely to 
be present, for example, at a field hospital or in low- 
resource settings. These issues may be less important 
when the focus of AST results is on infection preven-
tion and outbreak monitoring. In the latter case, several 
highly weighted factors that affect the development and 
implementation of novel AST platforms9 could include 
the comparative analysis of the effect of the implemen-
tation of new AST systems on laboratory efficiency and 
data quality, adequate communication between lab-
oratory data systems and decision- support tools, and 
surveillance tools for historical and current diagnostic 
information for infection prevention and the moni-
toring of local outbreaks of antibiotic- resistant patho-
gens. Preferably, efforts should be system agnostic and 
applicable to both existing and future AST platforms.
It should be noted that most clinical microbiologists 
are not yet ready to accept the implementation of AST- 
only systems, given the importance of establishing the 
identity of microbial species in the context of clinical 
decision making. According to EUCAST and CLSI 
guidelines, identification of pathogens at the species 
level is currently an essential element in interpreting 
minimum inhibitory concentrations (MICs) of anti-
biotics for particular pathogens. A paradigm shift will 
first be needed if physicians are to base their clinical 
decision making on AST- only platforms10. By contrast, 
it could be advisable to integrate AST platforms with a 
capacity for (limited) microbial identification in any new 
development process. MALDI- TOF mass spectrometry 
(MALDI- TOF-MS) may be well suited for this purpose.
There are also potential downsides to advocating 
the development of more rapid AST platforms. Major 
concerns would include lowered sensitivity and speci-
ficity as a consequence of abbreviated clinical validation 
studies or inadequate testing of low prevalence markers. 
Polymicrobial clinical samples could also influence test 
accuracy and, for instance, in molecular testing, asso-
ciating the right pathogen with the correct antibiotic 
resistance gene is crucial. Both laboratory personnel 
and clinicians are increasingly exposed to complicated 
information packages, and the correct management of 
such entities should result in more clinically actionable 
data. This suggests that large cooperative studies will be 
needed to guarantee an appropriate balance between the 
challenges listed above.
In this Consensus Statement, we present the barriers 
that are currently preventing the timely development 
and implementation of novel and rapid AST platforms, 
including the costs involved, uptake of new tools, legal 
and regulatory aspects, optimization of target prod-
uct profiles, difficulties conducting clinical trials and 
issues with quality and quality control. This Consensus 
Statement was developed following discussions on the 
current barriers to the implementation of new antimi-
crobial resistance testing formats and was facilitated 
by the Joint Programming Initiative on Antimicrobial 
Resistance (JPIAMR) Working Group on Rapid 
Diagnostic Testing (Supplementary Table 1).
Needs and barriers
Existing AMR traits are spreading globally, and resistance 
to newly licensed antimicrobials or novel mechanisms of 
resistance to older agents continue to emerge11,12. Many 
high- quality and recent scientific, economical, pub-
lic health- oriented and educational reports have been 
published on the subject13,14. Although these reports 
cover various AST- related subjects, with respect to AST, 
there are two basic diagnostic needs. First, there is the 
need for physicians to rapidly identify antibiotics that 
can be used to successfully treat patients infected with 
bacterial pathogens. Second, there is a need for epide-
miological assessment, that is, detecting phenotypic 
resistance mechanisms and monitoring their spread. 
As such, AST generates surveillance data and helps to 
design strategic actions to control AMR dissemination. 
These needs go hand- in-hand with the requirement to 
overcome diagnostic device implementation barriers 
(TaBle 1), and in this respect none of the new AST plat-
forms that are currently being developed (including the 
point- of-care (POC) tests, Box 2) are at the same level 
of clinical acceptance as classic routine AST methods. 
Although many of the newly proposed technologies 
show promising fields of application and good data, 
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Analysis of host factors (CRP and 
PCT) and direct, classic 
microbiological and molecular 
diagnostics
Microbiological identiﬁcation of 
the pathogen (biochemistry, mass 
spectrometry, molecular tools and 
DNA sequencing)
AST (phenotypic and/or genotypic 
tools, or genomic tools)
Fundamental research
Quantitative AST (semi-automated 
systems, disk diffusion, E-test or 
antibiotic dilution tests)
Does the patient have a bacterial 
or viral infection. If not, what 
causes ill health?
In the case of bacterial infection, 
what is the causative agent?
What is the antibiotic susceptibility 
proﬁle of the organism?
Does the organism seem to have 
unknown resistance markers?
What are the resistance levels to 
antibiotics?
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Fig. 1 | Triaging infections using diagnostic testing. Various technical means are 
available for identifying the causative agents of microbial infections and for generating 
antibiotic susceptibility profiles, which can inform the suitable course of treatment 
(diagnostic routing). First, host factors, such as C- reactive protein (CRP), procalcitonin 
(PCT) and others are analysed to, for instance, distinguish viral from bacterial infection. 
Following the identification of the causative bacterial pathogen, antimicrobial 
susceptibility testing (AST) is the next step (except in some specific molecular tests) to 
generate an antibiotic susceptibility profile. AST ensures that suitable antibiotics are 
prescribed to a patient. Beyond the outlined routine diagnostic process, there is 
opportunity to follow up with fundamental research to analyse the presence of novel 
resistance markers (possibly identifying novel resistance mechanisms) and to determine 
the resistance levels to the antibiotic.
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their current developmental status still prohibits direct 
clinical use. The major clinical needs identified in this 
section are aligned with the capacities of the current 
routine- applicable AST systems. For many of the newly 
suggested technologies, there are features that may still 
frustrate those clinical requirements.
Intellectual property and data protection. IP is a major 
driver in defining company policy. It defines compet-
itive advantages in the market on the basis of specific 
knowledge and expertise developed internally within 
companies by experimental and literature- based stud-
ies; such studies may result in new perspectives and 
Table 1 | barriers to the development and implementation of improved AST systemsa
barriers Effect on 
patient
Effect on 
user
Effect on 
manufacturer
Effect on 
policy maker
Competence of laboratory personnel x
Distance between clinicians and diagnosticians x
High cost of test x
Continuous availability in the laboratory x
Lack of clinical outcome studies x
Costs of clinical studies x
Costs of development x
Data management and poor electronic medical 
records
x
Finding partners (clinicians, laboratory directors, 
researchers, etc.) for clinical studies
x
Intellectual property challenges associated with 
multiple innovation
x
Laboratory decentralization and unlinked 
stewardship teams
x
Lack of appropriate marketing x
Lack of pre- market commitment x
Quality and availability of primary materials x
Policy makers not understanding the 
development process
x
Issues concerning sample taking x x
Specimen accessibility x x
Knowledge gaps of physicians or clinicians in 
the relevance of antimicrobial resistance
x x
Lack of funding x x
Storage, transport and stability of the test x x
Sample transport and other logistical issues x x
Supply chain failure x x
Limited exchange between diagnostic and 
pharmaceutical companies
x x
Lack of speed x x x
Test availability x x x
FDA validation and European certification (CE) 
including differences between countries
x x x
Biological hazard x x x
Ethical aspects x x x
Insufficient exchange between the public and 
private sector
x x x
Environmental aspects x x x x
Health practice behaviour x x x x
Communication (or lack thereof) x x x x
Lack of support programmes x x x x
aThe table is partially based on a prior key paper in this field81.
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practical inventions. Per definition, an invention is a 
creative technical solution to a technical problem that 
cannot be easily derived from the current state of the 
art and covers products (for example, devices, composi-
tions and molecules), methods and the use of methods15. 
Examples also include automation or methods of bar-
coding, the aesthetics of a design, an original artistic 
form or a distinctive sign. Inventions can be developed 
into trademarks, designs, copyrights and patents. Patents 
on inventions should be filed with an IP office and may 
be awarded after examination. The maximum life of a 
patent is 20 years, and the patent may be valid for only 
specific geographical areas. Patent protection is costly 
and depends on the geographical area that needs to be 
covered. Licensing of patents may reimburse some of the 
costs involved. However, in some cases, applying for a 
patent may not be advisable because trade secrets can 
be better protected by confidentiality.
In the field of informatics and big data, protection 
issues are complicated16. Databases of AMR gene variants 
are almost impossible to protect by IP. Although consid-
erable investments have been made to establish the data 
sets17, many of these databases are freely available online 
for academic use (for example, the Comprehensive 
Antibiotic Resistance Database)18. Of note, ongoing, 
large European Union- sponsored programmes are striv-
ing to generate high- quality, open access databases, with 
a focus on AST relating to the use of bacterial genome 
databases19–21. It remains to be seen whether the quality 
and curation of the databases will remain unaffected upon 
termination of such (grant- funded) programmes.
Management of IP and databases can pose barriers to 
the development of new AST systems; IP can be secured 
and not actively used by larger companies, thereby 
blocking further development, and databases need con-
stant and costly curation, which may present a barrier 
from a financial point of view. However, proper IP and 
data management provides competitive advantages 
when developed into commercially available AST tools.
Formal regulatory aspects and landscape. Clearance 
by the FDA is mandatory before marketing a diagnostic 
device in the United States for in vitro diagnostics (IVD) 
purposes. In some countries, including China, FDA reg-
istration may be a requirement in addition to the local 
registration needs. The main target of the procedure 
is to qualify and quantify safety, performance, risk of 
misinterpretation and the benefit–risk ratio. The FDA 
approval process is highly formal, and manufacturers 
seeking FDA approval for a rapid AST system should 
follow the published FDA guidelines. In the European 
Union, AST systems are regulated by the Directive 
98/79/EC (IVD directive). This is changing with the 
current introduction of the Regulation 2017/746 of 
the European Parliament and of the Council, which 
began in 2017. It requires design, development and 
manufacturing to be performed under a (still volun-
tary, except for Canada) quality system according to 
ISO 13485 (ISO is the International Organization for 
Standardization, which promotes the development 
and use of worldwide proprietary, industrial and com-
mercial standards). In the United States, the classifica-
tion of growth- based AST systems, or AST after initial 
growth, is well regulated. The Guidance for Industry and 
FDA: Class II Special Controls Guidance Document: 
Antimicrobial Susceptibility Test Systems (2009) was 
developed for the classification or re- classification of 
AST systems when the device is a system using short- 
term incubation (less than 16 h). In addition to this FDA 
guideline, the ISO standard 20776 adds further detail 
to the specifications and requirements for AST devices. 
A manufacturer who intends to market a device of this 
generic type must conform to the general controls of 
Section 513(a)(1)(B) of the Federal Food, Drug and 
Cosmetic Act, address the risks to health associated 
with the AST system and obtain a substantial equiva-
lence assessment from the FDA before marketing the 
device. Substantial equivalence to an already commer-
cially available device is loosely based on its intended 
use, the qualities of its design, the nature of the mate-
rials from which it is built, analytical performance, the 
safety of the user, effectiveness and some other even less 
strictly defined characteristics. The FDA believes that 
the performance of such a device can be best mapped 
by comparing it with the CLSI reference methods22–24.
Regulatory aspects can provide barriers to AST devel-
opment, as the clinical validation and trials are lengthy 
and costly, often too costly to be borne by a small- sized 
or medium- sized enterprise. In addition, there is an 
absolute need for specialized knowledge, which is not 
easy to acquire: experienced employees with this specific 
expertise are hard to find. Finally, discussion between 
companies and regulatory bodies may be compromised 
by the fact that there are differences in expertise between 
the two entities that do not always match.
Optimizing target product profiles. A target product 
profile (TPP) is a document that defines the layout and 
instruction for use of a commercial diagnostic test or 
device that will be developed into a product. A well- 
designed TPP directs a company to embark on a devel-
opment program that is efficient and lists all important 
Box 2 | Point- of-care antimicrobial susceptibility testing
antimicrobial susceptibility testing (ast) requires specific laboratory environments and 
instruments, and the availability of point- of-care (POC), point- of-need or point- 
of-impact ast is rare69. the exceptions are mainly DNa tests, which are capable of 
detecting resistance genes at all taxonomic levels, but still, they often require 
phenotypic verification32,70–73. this is unfortunate, as POC ast would enable the rapid 
and personalized treatment of infections, enabling clinicians to discern, for example, 
between Neisseria gonorrhoeae strains that are susceptible to currently frequently used 
antibiotics or require last- line antimicrobials25,74. POC ast could facilitate rapid 
diagnosis and treatment of major infectious diseases, such as tuberculosis, in low- 
income and middle- income countries75,76. a recent study77 described the use of 
decentralized rapid culture and an associated slow ast platform for the diagnosis and 
susceptibility testing of samples from patients suffering from urinary tract infections, 
which, although not fail- proof, could function well in remote regions. importantly, the 
price per test and the costs of the equipment will be major determinants for the 
implementation of POC ast. Compliance of POC ast with wHO assureD (affordable, 
sensitive, specific, user- friendly, rapid and robust, equipment free, deliverable to 
users78) criteria, which is especially relevant for low- income and middle- income 
countries, is to be hoped for but not expected soon79. in fact, all of the assureD criteria 
(although designed to ensure maximum implementation of POC testing in the target 
market) pose barriers to the development of POC ast80. POC tests need to be 
addressed individually to define their usefulness.
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medical, technical and scientific information needed to 
reach an optimal commercial outcome. On the basis of 
a recent definition, a TPP should be developed using 
efforts that include information provided by scientific 
researchers, funders and donors, policy makers, labora-
tory directors and clinicians, politicians and (industrial) 
test developers with respect to the optimal operational 
and clinical characteristics for the laboratories where the 
tests will be used25,26. Usually, existing diagnostic ecosys-
tems and diagnostic development landscapes need to be 
surveyed, and a TPP will vary depending on the site, the 
purpose and the target group intended for implementa-
tion of the test. Some important considerations concern 
quality control, maintenance and calibration, the ability 
to export data and performance- related requirements 
such as the TTR, sensitivity and specificity, as well as 
the hands- on and training time. There are desired and 
minimum requirements set in a TPP that should define 
the needs of the diagnostic stakeholders and provide a 
means of communication with test developers to ensure 
that fit- for-purpose systems are developed.
The development of a new AST system starts with 
an idea and ensuing product development until final 
commercialization. In between are many important 
steps (Fig. 2) at which an extensive version of a product 
development scheme is presented. Not all companies 
will use exactly the same scheme, but the different steps 
shown are key in appropriate guidance of a develop-
ment plan. As such, a TPP description is followed by 
a product development plan (PDP), which generally 
consists of six distinct phases. Phase 0 is when a busi-
ness proposal is composed and IP issues are studied. 
The latter involves not only the management of pro-
prietary IP but also the analyses of freedom to operate 
and competing IPs. This implies that a concept prod-
uct already exists and proof of principle and proof of 
concept have been achieved. At the end of phase 0, a 
product design review (PDR) is performed whereby an 
independent panel of experts judges and validates the 
product. PDRs are managed by a design review com-
mittee consisting of experts in various domains of test 
development (for example, legal, business development 
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Fig. 2 | Schematic overview of the development process for products in the in vitro diagnostics market. The product 
development plan (PDP) consists of six distinct phases. The business proposal is composed during phase 0, usually taking 
results of basic research into consideration. Definition and feasibility studies are performed in phase 1, followed by design 
and verification in two separate phases (2a and 2b). Phase 3 involves validation, and the final phase, phase 4, comprises 
commercialization. To streamline this process, there is an initial business plan review (BPR) and subsequent phase reviews 
(P0R to P4R) after all phases. During phase 1, a product requirements document (PRD) is developed. The PRD takes into 
account all technical and medical needs this product should ultimately meet. The project decision may still lead to 
changes in the overall planning. New product introduction (NPI) is a distinct process (in parallel with the PDP) that focuses 
on the successful introduction of the new product. Whereas the PDP is mostly focused on technical and medical 
requirements, the NPI also takes customer requirements, market needs, pricing, medical–economic value and other 
parameters into account. For the NPI, similar reviews are planned during the process, which go straight from the business 
plan (BP) to launch planning (LP). At two stages, very important development decisions are taken. At the end of phase 1, an 
‘OK’ is needed, as well at the end of phase 3. At these stages, labour- intense and costly further development stages will be 
agreed upon by the development team. The boxes below the planning schemes identify some of the most important 
parameters that are studied during the various stages of the PDP and NPI. Note that specific investigations and changes 
are continually being investigated at the various stages. The dashed line implies the possibility for a development process 
to still be aborted during these phases. From phase 2a onward this is much less likely to happen. KOLs, key opinion leaders; 
R&D, research and development.
Nature reviews | Microbiology
C o n S e n S u S  S tat e m e n t
and technology). Definition and feasibility studies are 
performed next (phase 1), followed by another PDR in 
two separate phases (2a and 2b). Phase 3 involves valida-
tion, which is then followed by a third PDR. Entry into 
the final phase 4 (commercialization) requires a fourth 
PDR. This protocol requires documentation and (long- 
term) data storage. New product introduction (NPI) is 
a distinct process (in parallel with the PDP) that focuses 
on the successful introduction of the new product (the 
ultimate target being product launch) (Fig. 2). Project risk 
management, safety risk management, design optimiza-
tion and design transfer are just some of the obligatory 
processes that need to safeguard the quality of product 
development. Mandatory documents are the design his-
tory file, the risk management file and the design output 
and device master record. Obviously, product planning 
encompasses many stakeholders.
For all AST products, the process outlined above 
needs to be considered before FDA approval (TaBle 2). 
Only tests that have passed that ultimate FDA approval 
step can be marketed as being IVD compatible. Even 
though small- sized and medium- sized enterprises may 
offer innovation and a flexible attitude, it is consider-
ably easier for larger diagnostics companies with the 
necessary critical mass and financial backing to accu-
mulate expertise in clinical development, regulatory 
aspects and communication and to undertake extensive 
(and therefore expensive) clinical studies27. This is a 
substantial barrier to market penetration of new prod-
ucts developed by small companies. For these reasons, 
several small companies have succeeded via partnering 
with larger companies in the final development stages. 
New modes of financing preclinical validation research 
and sponsorship for defraying the costs of more formal 
development steps are therefore required. Optimal train-
ing of customers and high- class field support in case of 
problems are key for manufacturers.
Management and regulation of quality management 
systems. A quality management system (QMS) is a for-
malized system of policies, processes, procedures and 
responsibilities required for planning and execution 
in all areas of an organization that are in contact with 
the product or the customer. This includes develop-
ment, marketing, manufacturing, sales, supply chain 
and customer service. It helps to coordinate and direct 
activities to continuously meet customer and regulatory 
requirements. Starting the implementation of a QMS 
early in product development with the support of out-
side specialized consultants will help shaping a QMS for 
acceptable investments.
A QMS is needed to comply with IVD regulations. 
Its latest possible time point for implementation is after 
proof- of-principle studies have been performed, when 
completing phase 0 (Fig. 2). This implies that after finali-
zation of the TPP and the feasibility studies, a QMS 
should be in place. Otherwise, AST development will 
slow down, with the risk of the project being compro-
mised (for example, by rising costs of development). 
QMS development will be important in the transition 
from basic AST research to the establishment of a rou-
tine AST platform. A good and flexible QMS system 
enables planned deviations from the standard develop-
ment process and minimizes the re- development of aca-
demic findings. A QMS guarantees the quality control 
and assurance of new tests to provide optimal test quality 
to both the users in the diagnostic laboratories and the 
patients subjected to testing.
There is no way to abrogate the QMS in PDPs, as gov-
erning bodies will not accept registration efforts. We feel 
that there is no need for a fully implemented QMS for 
research in academia but that having a global knowledge 
of quality requirements would be helpful in preventing 
development without quality assessment. We emphasize 
that close interactions and collaborations between aca-
demic institutes and industry should be initiated very 
early in the diagnostic development process to ensure 
that scientific discovery, invention and development 
processes are productively coupled.
Quality assessment programmes and assessment of 
the impact of quality improvement strategies are essen-
tial in evaluating the performance of new AST platforms 
in the microbiology laboratory. Survey reports, infor-
mation bulletins, correspondence, on- site consultations, 
educational assistance tutorials and education are used as 
quality improvement strategies that need to be repeated 
on an annual basis28. Improvement in QMS is strongly 
dependent on external assessment and education. 
European organizations (for example, the UK National 
External Quality Assessment Service (NEQAS) and 
Quality Control of Molecular Diagnostics (QCMD)) help 
to exert external comparative quality assessment in good 
detail29–31. Although regulations must be complied with, 
quality standards (as defined by recognized governing 
bodies such as, for example, the ISO, the FDA, European 
Commission and the European Medical Device Vigilance 
System (MEDDEV)) can be applied voluntarily and have 
been developed through a consensus process. Regulations 
and standards are fundamental to developing harmonized 
procedures to the advantage of customers and users of 
AST systems. A QMS integrates the elements required 
by regulation, standardization and guidance documents. 
The most important regulations in the AST development 
and implementation domain are issued by the FDA with 
their code of federal regulations32. In addition, the IVD 
directive 98/79/EC and IVD regulation 2017/746 are 
the main European drivers towards regulation (among 
others). For standardization, the ISO has an impor-
tant role, issuing standards for QMSs (ISO 9001:2015), 
risk management (ISO 14971:2012), product labelling 
(ISO 18113) and stability (ISO 23640:2011), among 
others. Guidelines on quality management for medi-
cal devices have been issued by the European Union 
(MEDDEV 214/3;2007), and such devices are covered 
by ISO 13485:2016. The QMS should ensure appropriate 
data management, customer satisfaction, improvement 
opportunities, quality analysis and ultimately product 
quality. Overall this should reduce waste, lower produc-
tion costs, engage staff and meet customer expectations. 
AST platform test qualities are defined by sensitivity, 
specificity and positive and negative predictive values, 
which are parameters that should be covered by quality 
assurance and external validation studies33,34. Importantly, 
the FDA has defined guidance for the use of test devices 
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in the domain of human genomic testing, and it is anti-
cipated that similar guidance for the molecular identi-
fication and characterization of microbial species and 
their phenotypes, including resistance to antimicrobials, 
will (have to) follow soon35.
Assessment and evidence of clinical utility and validity. 
It is generally accepted that AST systems should always 
be available (that is, at any time of any given day) and 
should be more rapid. Results should preferably be avail-
able in less than 1 h from sampling, but a time frame 
within a single working shift would be a major improve-
ment. This may depend on the actual focus of the test, 
and the medical–economic value of new AST platforms 
should be substantial. It has been claimed that the 
results of diagnostic microbiology testing affect clini-
cal therapy decision making for about 50% of patients, 
whereas results generating changes from empiric to 
more targeted antibiotic therapy involve 34% to 56% 
of patients36. Assuming that bacterial identification 
has been already performed and is not a limiting fac-
tor, paediatric infectious disease specialists seem to 
Table 2 | global requirements for the development of a new AST platform before submission of the file to the FDA
general requirements Specification
Intended use statement • The intended use should be specified and be representative of the target populations tested with good 
performance characteristics
• The intended use must indicate organism groups and any instrumentation the device may be used with
• An example of a typical intended use statement: the ABC system is intended for the in vitro qualitative or 
quantitative determination of antimicrobial susceptibility of rapidly growing aerobic non- fastidious Gram- 
positive and Gram- negative organisms on the ABC Instrument
Summary and explanation of the test • The summary and explanation of the test section must include whether the assay is quantitative (MIC) or 
qualitative (RIS) and whether results may be read and reported manually
Principle of the method • The principles must be explained
• A concise description of the technological features of the device and how the device is to be used with 
patient samples needs to be included
Reagents • Antibiotics and the concentration ranges and abbreviations must be listed. These must be included in the 
reagent section of the labelling or on each package container if different for different devices
• To prevent confusion between different drugs with similar names, abbreviations as recommended by their 
manufacturer should be used
• The product insert should be flexible to accommodate additional antimicrobial agents
• Charts should be used when possible to facilitate additions of future antimicrobial agents, limitations and 
performance characteristics
Directions for use • A step by step outline of recommended procedures must be presented
Quality control • The step by step outline of the procedure must describe quality control procedures and materials required 
with details of calibration
• It should be ensured that the specifics of calibration and quality control are well aligned with performance 
claims
• All recommended quality control strains and the expected results when tested with each antimicrobial 
agent must be defined
Reporting of results • The interpretive criteria for each antimicrobial agent on the MIC or breakpoint device based on the FDA 
interpretive standards must be explained
• Automated systems should have the interpretations included in the software, but if manual readings are an 
option, a chart of thresholds to be used for susceptibility , intermediate resistance and full resistance (RIS) 
interpretations must be included
• Results should not be reported in instances when good performance has not been established
• FDA suggests that suppression of results be software driven
Limitations • Statements of limitations of the procedure are mandatory
• If the device has software- generated interpretations, these limitations should be incorporated into the 
software
• The following are examples:
-  Recommend the use of an alternative method prior to reporting of any results when the activity for any 
antibiotic suggests organisms with unacceptable very major error or major error rates
-  If not enough resistant organisms were tested, this should be mentioned. This limitation may not be 
necessary if a sufficient number of evaluable results close to the interpretative categories are available
-  If the reproducibility results for any antimicrobial agent using one procedural option are not reproducible 
while another option is reproducible, one should take a limitation against reporting results
-  An alternate method for any organism group that had a ‘no growth’ rate greater than 10% should be 
recommended. AST systems may be able to provide results for organisms that may not be appropriate for 
all of the antimicrobial agents provided on a test panel or system
Performance characteristics • Specific performance characteristics of the assay , including the study design, stating the reference method 
used, and the number of sites, must be included
• The percentage of essential and/or categorical agreement must be shown in table format with the 
reference method for each antimicrobial agent from comparative performance evaluations
• Results of reproducibility studies in either a table format or a summary paragraph describing the type of 
study and a statement that all reproducibility results were acceptable at greater than 95% must be included
AST, antimicrobial susceptibility testing; MIC, minimum inhibitory concentration; RIS, resistant, intermediate and susceptible.
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be the most frequent users of AST services, whereas 
emergency room doctors request the smallest number 
of such tests. However, the availability of and access 
to accurate and rapid AST will not always result in 
increased use of either the service or the data generated. 
According to recent market feedback, both inpatients 
and outpatients are not willing to delay their first dose 
of antimicrobials for 15 min and even less are willing 
to delay for 30 min (G.L., unpublished observations). 
Therefore, rapid AST systems will mostly have a role 
in the switch to better defined therapy37–39. Still, to 
implement rapid AST systems, we need better delivery 
of diagnostic care to provide better clinical care at the 
same time. Even so, generating accurate susceptibility 
profiles before the second dose of empirical therapy 
would offer major advances in the treatment of bacterial 
infections and antibiotic stewardship. Clinical trials and 
behavioural change, to be defined for different hospi-
tals with sometimes large differences in organization, 
may be required to determine the actual added value 
of waiting up to 1 h (‘watchful waiting’ approach) for 
an AST result compared with the immediate admini-
stration of an antibiotic. It has to be emphasized that 
detection of possibly small but major differences in 
terms of value added may need large and costly clinical 
studies. Nevertheless, it seems obvious that the decision 
between immediate treatment versus waiting for a sus-
ceptibility profile and more targeted treatment should 
be based on the (perceived) urgency of the clinical situ-
ation of the patient. Finally, all efforts into rapid AST 
are useless if pre- analytical factors (including sample 
transport) are neglected. The urgency for rapid AST 
will automatically increase with the emergence of more 
multidrug- resistant bacterial species.
Cost- effectiveness and health economics studies. 
The cost of consumables accompanying traditional 
microbial identification and AST (such as agar plates, 
liquid media and commercial diagnostic systems) has 
always been relatively modest, with the main budget 
expense in a clinical microbiology laboratory being 
cost of labour40. AST results are often not released 
from the instrument for hours. Currently, the value 
of the introduction of expensive diagnostics has been 
quite selectively studied during the implementation 
of nucleic acid- based quantitative detection, whereby 
the test is offered to only a well- defined patient popu-
lation (such as patients infected with HIV or hepatitis 
C virus). The availability of a somewhat costly direct- 
from-blood, nucleic acid- based detection platform for 
microbial pathogens and resistance markers did not 
immediately show its medical value to the individual 
patient41. However, the Roche SeptiFast assay and the 
Abbott Iridica test42 were never broadly implemented 
and thus were unsuccessful; both were too expensive 
to be made available to all patients, and their uptake in 
the diagnostic market failed. The systems were never 
made available to the US market, so it is not known 
whether they might have done better in the American 
medical ecosystem. Still, the characteristics of the two 
tests and their performance relative to existing diagnos-
tics were not viewed as justification for their proposed 
clinical benefit. On the basis of theoretical assumptions, 
probably fewer than 20–25% of all patients may bene-
fit from such add- on diagnostic tools41. Still, negative 
test results and the evidence for discontinuation of 
treatment will ultimately have a distinct value only if a 
satisfactory negative predictive value of the test can be 
demonstrated. Relatively expensive tests in health- care 
economies that require the patient or an insurer to pay 
for or reimburse the cost of a diagnostic test may not 
represent good odds. Without the preselection of high- 
risk patients, any added value will be diluted by the 
large number of patients who will not gain benefit from 
the new platform. At the level of an individual hospital 
laboratory, which very often has a limited budget, it is 
hard to demonstrate the relevance of possible savings 
following the implementation of new microbial diag-
nostic platforms. The real impact and cost savings 
incurred by new AST platforms are more likely to be 
felt in actual clinical departments rather than in the 
laboratory, hence in a budget silo where the primary 
costs for testing are not actually paid for. The differ-
ence in speed between many of these systems and an 
accelerated conventional phenotypic test (disk diffusion 
or a gradient test) recalibrated to shorter incubation 
time (4–8 h) is only very small or non- existent, and the 
question remains whether this correlates with improved 
clinical effectiveness. The successful implementation 
of relatively expensive diagnostic systems will require 
prospective clinical outcome studies, as well as the 
development of personalized diagnostics approaches. 
Personalized diagnostics will require an upfront risk 
assessment to select high- risk patient cohorts; the gen-
eral concept of individual risk assessment has already 
been accepted by the clinical community. However, the 
value to patient management and the outcome of a sys-
tematic risk assessment, as an upfront gatekeeper for 
access to relatively expensive diagnostic assays, has not 
yet been evaluated. There is a global need for integrative 
systems- based practices covering clinical care, diagnos-
tics, treatment and intelligent antibiotic stewardship. 
Improvement in availability and use of electronic med-
ical records (EMR) would be an important step in the 
right direction.
Risk assessments based on machine learning or 
causal probabilistic network analyses have been applied 
to population- based predictions of major outbreaks of 
infection43, as well as in the risk assessment of individual 
patients44. A new algorithm was able to select patients 
at a higher risk of systemic infection. Future clinical 
outcome studies may identify other potential risk fac-
tors associated with predicting the individual risk (or 
likelihood of risk) of infected patients without the use 
of expensive add- on diagnostics that may provide faster 
AST and thus an improved clinical outcome. A detailed 
comparison between clinical scenarios in developed 
and developing economies is required. Funding models 
around insurance and reimbursement should be made 
more attractive and go beyond the classic governmen-
tal research incentive. Specific funds for development, 
industrialization and product design should be made 
available, which would promote the uptake of innovative 
AST strategies.
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Applications
Antimicrobial susceptibility testing and new 
antibiotics. AST and AMR surveillance are important 
parts of the development of new antibiotics, as infec-
tion prevention and infectious disease practitioners will 
not generally introduce a new antibiotic into health care 
until they understand its use45. Furthermore, AST data 
and proposed breakpoints for new antibiotics have to 
be submitted as part of regulatory approval procedures. 
Investing in AST during antibiotic development could 
help reduce the costs of clinical trials46. Co- development 
of new antimicrobials together with specific AST for 
target microorganisms may help to better position an 
antibiotic in the clinical market47. In an era of pan- drug 
resistance, we are reconsidering empiric broad- spectrum 
antibiotic- prescribing policies, and the identification of 
bacterial resistance to novel antimicrobials using AST 
may not necessarily mean that an already available, or 
previously ‘shelved’, antibiotic needs to be discarded but 
that it needs to be considered in alternate prescribing 
schemes such as antibiotic mixing or cycling48. Novel and 
rapid AST should be versatile and adaptable to changes 
in the way in which (new) antibiotics are prescribed, 
both currently and in the future.
The institutional antibiogram. As a means to drive 
the use of AST data as part of the accreditation process 
for clinical microbiology laboratories leading to the 
certification by the Clinical Laboratory Improvement 
Amendments (CLIA), the College of American 
Pathologists (CAP) publishes a checklist of guidelines 
that includes a call for the construction of an annual 
institutional cumulative antibiogram to assess local 
AMR trends. Specifically, MIC.21946 mandates that 
certified laboratories maintain cumulative AST data 
and report these to medical staff at least once a year. 
CLSI has developed guidelines (the most recent being 
M39-A4)49 to provide a standardized template for the 
preparation of institutional antibiograms50. An effort to 
generate data that can be compared between reporting 
periods and between institutions means that the rules 
for this guideline have become fairly complex, although 
the basic principles of M39-A4 remain, including an at 
least annual cumulative antibiogram report that contains 
only verified final results. The cumulative data should 
include antibiotics that are routinely used by the report-
ing institution. However, even in this format, it should 
be noted that the yearly institutional antibiogram might 
not provide feedback that is sensitive enough to meas-
ure the effectiveness of antimicrobial stewardship inter-
ventions but could provide advice when a unit- specific 
antibiogram is used51. The institutional antibiogram 
functions as a guide for automatically selecting the cor-
rect therapy for infections in cases when the causative 
microorganism has been identified50. Two recent publi-
cations have used existing institutional antibiograms to 
develop a Weighted- Incidence Syndromic Combination 
Antibiogram (WISCA)52,53. The authors considered 
the effectiveness of empiric antibiotic prescribing for 
monomicrobial or polymicrobial infections before AST 
results had even been generated. They used information 
(specific organism–antibiotic combination effectiveness 
assumptions) gained from traditional antibiograms 
as a guide.
An institutional antibiogram may be integrated in 
machine learning- based software. Machine learning is 
used for the development of explicit algorithms with 
predictive power and is closely related to computational 
statistics. Within the field of data analytics, machine 
learning is a method used to design complex models 
that lend themselves to prediction. Adoption of these 
models will enable AST researchers to suggest reliable 
decisions and uncover new insights through learning 
from historical antibiotic resistance data trends. Such 
decision- support software programmes may provide 
guidance for optimal empirical antimicrobial treatment 
on the basis of available clinical and laboratory informa-
tion in the electronic patient record and information on 
local microbial flora and AMR profiles44.
The ‘smart antibiogram’. Although the institutional 
antibiogram is a powerful tool, it will never eliminate 
the need for new and improved AST systems. The cur-
rent frequency at which these antibiograms are updated 
may mean that they are not quickly adaptable to rapidly 
changing or emerging antibiotic resistance mechanisms 
that occur within a particular health- care institution54. If 
we consider recent and future technological advances in 
the rapid identification of the causative agent, for exam-
ple, the use of molecular assays or MALDI- TOF-MS 
to detect microorganisms directly from positive blood 
culture bottles, then a more refined system for suscep-
tibility (or resistance) could be generated via a ‘smart 
antibiogram’. First, the smart antibiogram has to have 
real- time access to rapid cumulative antibiotic profiling 
data and be essentially self- updating with all the appro-
priate rules and logic in place to aggregate relevant anti-
biotic profiling data. Again, in this case, accessible EMRs 
would be important, although there may be issues with 
non- discrete microbiological data and rules. A smart 
antibiogram system must also have the flexibility to 
identify trends or parameters on the basis of increases 
in individual antibiotic MICs via the addition of mul-
tidrug resistance rules and alerts to the algorithm used. 
Second, by limiting the number of isolates recorded per 
patient to the initial isolate only, the M39-A4 guidelines 
prevent extrapolation of resistance profiles. If the same 
multidrug- resistant microorganism was recovered from 
the blood, urine and respiratory secretions of a single 
patient yet only the blood isolate was represented in the 
cumulative antibiogram, the data would not reflect 
the overall susceptibility of all isolates recovered from 
urine or respiratory tract specimens. Further, this pro-
cedure does not enable antimicrobial stewardship or 
infection prevention personnel to observe the accumu-
lation of antibiotic resistances in patient isolates during 
the course of antibiotic therapy.
Using AST data from single patient isolates recovered 
from different sources would enable search parameters 
to include the selection of both specimen type55–60 and 
specific organisms59–61, thereby providing more realistic 
algorithms to guide empiric treatment. Antimicrobial 
prescription and institutional antibiograms differ 
between various institutions, sometimes even within 
an individual health- care institution60,62,63, and between 
inpatient and outpatient populations60,63–65. They may 
change on the basis of length of hospital stay66 and 
may depend on the age of the patient65,67. In addition, 
more specific attributes of the causative microorganism, 
for example, the presence of antibiotic- resistant popula-
tions61 or whether an organism was recovered through 
surveillance culture or from a diagnostic specimen64, 
could be recorded. Therefore, the smart antibiogram 
should be developed to use a whole range of search 
parameters and patient demographics in its calcula-
tions. This will facilitate the automatic fine tuning of 
smart antibiogram algorithms and increase their value 
in predicting the correct empiric antibiotic therapy for 
individual microorganisms detected in different clinical 
specimens at different times on different wards and from 
different populations. For that, statistical approaches 
must be developed that would help predict correct anti-
biotic treatment on the basis of prior experience and the 
use of intelligent databases.
Concluding statements
AST is an important part of the targeted antibiotic- 
prescribing process for bacterial diseases, helping to 
cope with and reduce the growing emergence and 
spread of AMR, informing on the success of infection 
control measures and ultimately saving the lives of 
patients. However, there still remains a need for novel 
and rapid AST diagnostics to be developed and imple-
mented, which is not always appreciated by clinicians 
and health- care authorities. For example, it seems logical 
that appropriate AST approaches should be considered 
a major factor for monitoring and responding to infec-
tious disease outbreaks. Yet, even recent publications68 
tend to pay little attention to the need for AST in help-
ing limit and prevent outbreaks. Better communication 
about the importance of AST should lead to better col-
laboration between the public, academia, patient groups, 
policy makers and industry. Understanding AST plat-
form development and implementation issues will lead 
to a better understanding of the barriers and solutions 
required by public and private entities in maximizing the 
availability and use of (new and rapid) AST platforms. 
The AST platforms that are currently available are robust 
and represent added value to the clinical diagnostic 
microbiology laboratory, but their main shortcoming is 
the somewhat long TTR and lack of automation. The 
TTR of traditional AST is being reduced from 16–20 h to 
4–8 h but requires recalibration when doing so, includ-
ing, for example, AST tests that generate MICs. New 
AST platforms have been developed and proposed, but 
there is a lack of market penetration and, hence, further 
innovation. In this Consensus Statement, we presented 
barriers and possible solutions to the development and 
implementation of AST in health- care settings, ulti-
mately resulting in the potential use of institutional 
smart antibiograms. We hope that this knowledge will 
lead to increased dialogue and understanding between 
AST developers and end users, leading to a positive 
impact on patient care.
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